Mette Marie H Christensen1, Kurt Højlund2,3, Ole Hother-Nielsen2, Tore B Stage4, Per Damkier4,5, Henning Beck-Nielsen2, Kim Brøsen4. 1. Department of Public Health, Clinical Pharmacology, University of Southern Denmark, J.B. Winsloews Vej 19, 5000, Odense, Denmark. mmchristensen@health.sdu.dk. 2. Department of Endocrinology, Odense University Hospital, Odense, Denmark. 3. Section of Molecular Diabetes & Metabolism, Institute of Molecular Medicine & Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. 4. Department of Public Health, Clinical Pharmacology, University of Southern Denmark, J.B. Winsloews Vej 19, 5000, Odense, Denmark. 5. Department of Clinical Chemistry and Pharmacology, Odense University Hospital, Odense, Denmark.
Abstract
AIMS/HYPOTHESIS: Metformin is believed to reduce glucose levels primarily by inhibiting hepatic glucose production. Recent data indicate that metformin antagonises glucagon-dependent glucose output, suggesting that compensatory mechanisms protect against hypoglycaemia. Here, we examined the effect of metformin on glucose metabolism in humans after a glycogen-depleting fast and the role of reduced-function alleles in OCT1 (also known as SLC22A1). METHODS: In a randomised, crossover trial, healthy individuals with or without reduced-function alleles in OCT1 were fasted for 42 h twice, either with or without prior treatment with 1 g metformin twice daily. Participants were recruited from the Pharmacogenomics Biobank of the University of Southern Denmark. Treatment allocation was generated by the Good Clinical Practice Unit, Odense University Hospital, Denmark. Variables of whole-body glucose metabolism were assessed using [3-(3)H]glucose, indirect calorimetry and measurement of substrates and counter-regulatory hormones. The primary outcome was endogenous glucose production (EGP). RESULTS:Thirty-seven individuals were randomised. Thirty-four completed the study (12 had none, 13 had one and nine had two reduced-function alleles in OCT1). Three were excluded from the analysis because of early dropout. Metformin significantly stimulated glucose disposal rates and non-oxidative glucose metabolism with no effect on glucose oxidation. This increase in glucose utilisation was explained by a concomitant increase in glycolytic flux and accompanied by increased EGP, most likely mediated by increased plasma lactate, glucagon and cortisol levels. There was no effect of reduced-function OCT1 alleles on any of these measures. All individuals completed the glycogen-depleting fast without hypoglycaemia. CONCLUSIONS/ INTERPRETATION: Metformin stimulates glycolytic glucose utilisation and lactate production in the glycogen-depleted state. This may trigger a rise in glucose counter-regulatory hormones and subsequently an increase in EGP, which protects against hypoglycaemia. TRIAL REGISTRATION: ClinicalTrials.gov NCT01400191 FUNDING: Danish Research Council for Health and Disease (0602-02695B) and Odense University Hospital Free Research Fund, 2012.
RCT Entities:
AIMS/HYPOTHESIS: Metformin is believed to reduce glucose levels primarily by inhibiting hepatic glucose production. Recent data indicate that metformin antagonises glucagon-dependent glucose output, suggesting that compensatory mechanisms protect against hypoglycaemia. Here, we examined the effect of metformin on glucose metabolism in humans after a glycogen-depleting fast and the role of reduced-function alleles in OCT1 (also known as SLC22A1). METHODS: In a randomised, crossover trial, healthy individuals with or without reduced-function alleles in OCT1 were fasted for 42 h twice, either with or without prior treatment with 1 g metformin twice daily. Participants were recruited from the Pharmacogenomics Biobank of the University of Southern Denmark. Treatment allocation was generated by the Good Clinical Practice Unit, Odense University Hospital, Denmark. Variables of whole-body glucose metabolism were assessed using [3-(3)H]glucose, indirect calorimetry and measurement of substrates and counter-regulatory hormones. The primary outcome was endogenous glucose production (EGP). RESULTS: Thirty-seven individuals were randomised. Thirty-four completed the study (12 had none, 13 had one and nine had two reduced-function alleles in OCT1). Three were excluded from the analysis because of early dropout. Metformin significantly stimulated glucose disposal rates and non-oxidative glucose metabolism with no effect on glucose oxidation. This increase in glucose utilisation was explained by a concomitant increase in glycolytic flux and accompanied by increased EGP, most likely mediated by increased plasma lactate, glucagon and cortisol levels. There was no effect of reduced-function OCT1 alleles on any of these measures. All individuals completed the glycogen-depleting fast without hypoglycaemia. CONCLUSIONS/ INTERPRETATION:Metformin stimulates glycolytic glucose utilisation and lactate production in the glycogen-depleted state. This may trigger a rise in glucose counter-regulatory hormones and subsequently an increase in EGP, which protects against hypoglycaemia. TRIAL REGISTRATION: ClinicalTrials.gov NCT01400191 FUNDING: Danish Research Council for Health and Disease (0602-02695B) and Odense University Hospital Free Research Fund, 2012.
Authors: S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews Journal: Diabetologia Date: 2012-04-20 Impact factor: 10.122
Authors: Tore B Stage; Per Damkier; Rasmus S Pedersen; Mette M H Christensen; Lene Christiansen; Kaare Christensen; Kim Brosen Journal: Pharmacogenet Genomics Date: 2015-05 Impact factor: 2.089
Authors: Peter Staehr; Ole Hother-Nielsen; Henning Beck-Nielsen; Michael Roden; Harald Stingl; Jens J Holst; Paul K Jones; Visvanathan Chandramouli; Bernard R Landau Journal: Am J Physiol Endocrinol Metab Date: 2007-01-09 Impact factor: 4.310
Authors: R S Hundal; M Krssak; S Dufour; D Laurent; V Lebon; V Chandramouli; S E Inzucchi; W C Schumann; K F Petersen; B R Landau; G I Shulman Journal: Diabetes Date: 2000-12 Impact factor: 9.461
Authors: E Bonora; M Cigolini; O Bosello; C Zancanaro; L Capretti; I Zavaroni; C Coscelli; U Butturini Journal: Curr Med Res Opin Date: 1984 Impact factor: 2.580
Authors: T Dujic; K Zhou; S W Yee; N van Leeuwen; C E de Keyser; M Javorský; S Goswami; L Zaharenko; M M Hougaard Christensen; M Out; R Tavendale; M Kubo; M M Hedderson; A A van der Heijden; L Klimčáková; V Pirags; A Kooy; K Brøsen; J Klovins; S Semiz; I Tkáč; B H Stricker; Cna Palmer; L M 't Hart; K M Giacomini; E R Pearson Journal: Clin Pharmacol Ther Date: 2017-02-03 Impact factor: 6.875
Authors: Anders Hostrup Larsen; Henrik Wiggers; Ole Lindgård Dollerup; Nichlas Riise Jespersen; Nils Henrik Hansson; Jørgen Frøkiær; Kim Brøsen; Helene Nørrelund; Hans Erik Bøtker; Niels Møller; Niels Jessen Journal: Cardiovasc Drugs Ther Date: 2020-08-08 Impact factor: 3.727
Authors: Tabassum Moonira; Shruti S Chachra; Brian E Ford; Silvia Marin; Ahmed Alshawi; Natasha S Adam-Primus; Catherine Arden; Ziad H Al-Oanzi; Marc Foretz; Benoit Viollet; Marta Cascante; Loranne Agius Journal: J Biol Chem Date: 2020-01-23 Impact factor: 5.157
Authors: Zulfan Zazuli; Naut J C B Duin; Katja Jansen; Susanne J H Vijverberg; Anke H Maitland-van der Zee; Rosalinde Masereeuw Journal: Int J Mol Sci Date: 2020-09-10 Impact factor: 5.923